Noax uno

Quick links to important sections

Noax uno

Treatment option: Pain, Chronic Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noax uno

Property Description
Active ingredient Tramadol Hydrochloride
Form Oral Tablet (Extended-Release)
Pharmacological class Opioid Analgesic, Centrally Acting
Common use Management of moderate to severe pain
Origin Synthetic compound

What Type of Analgesic is Noax uno?

Noax uno is a medicinal product whose active component is Tramadol Hydrochloride, classified as a synthetic, centrally acting opioid analgesic. This designation means the drug primarily exerts its pain-relieving effects within the brain and spinal cord, modifying the body’s perception of pain signals. The compound acts directly on the central nervous system to achieve these effects. As a prescription-only medication, Noax uno is differentiated by its specific focus on adult patients requiring sustained management for significant discomfort.


Composition and Dosage Form of the Product

The preparation is formulated as a single-ingredient oral dosage form, presented as a tablet intended for ingestion. The core composition involves the active substance, Tramadol Hydrochloride, combined with necessary pharmaceutical excipients that form the tablet matrix. A key differentiating feature of Noax uno is its specialized extended-release (ER) formulation, which is specifically designed to control the rate at which the active ingredient is released into the bloodstream. This sustained-release mechanism allows for consistent analgesic coverage, which is particularly beneficial for patients with chronic pain conditions requiring continuous relief throughout the day.


The General Purpose of Noax uno

The primary therapeutic purpose of Noax uno is to provide powerful analgesia by modulating pain signals centrally. The drug achieves this through a dual mechanism that involves both binding to specific opioid receptors and inhibiting the reuptake of neurotransmitters like norepinephrine and serotonin. This combined approach makes the medication suitable for managing moderate to severe pain that significantly affects a patient's quality of life, offering a therapeutic option when conventional pain relievers are insufficient.

What side effects are possible with Noax uno?

Possible Side Effects and Safety Information

The safety profile for Noax uno (ketoprofen 200 mg prolonged-release) is based on official government regulatory documents. The profile is structured by categorizing known adverse reactions by their system-organ class and frequency.

Serious Adverse Reactions

The most significant and serious risks documented for this medicine primarily involve the gastrointestinal (GI) and cardiovascular systems. GI risks include the potential for ulcers, bleeding, or perforation, which can occur without warning symptoms and may be fatal. Cardiovascular risks include an association with serious thrombotic events, such as myocardial infarction (heart attack) and stroke, particularly with high doses or long-term use. Other serious documented risks include severe allergic reactions (anaphylaxis, angioedema), severe skin reactions (Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), and severe renal or hepatic failure.

Frequency-Classified Effects

Frequency Examples of Adverse Reactions (by SOC)
Common (1 to 10 in 100 people) Dyspepsia, nausea, abdominal pain, vomiting
Uncommon (1 to 10 in 1,000 people) Headache, dizziness, fatigue, skin rash, oedema (swelling)
Rare (1 to 10 in 10,000 people) Peptic ulcer, stomatitis, blurred vision, haemorrhagic anaemia

Safety Restrictions and Contraindications

This medicine is contraindicated (must not be used) in the presence of certain conditions due to the risk of serious harm. These restrictions include, but are not limited to, active or recurrent peptic ulcers or hemorrhage, history of GI bleeding related to previous NSAID use, severe heart, kidney, or liver failure, and during the third trimester of pregnancy due to risk to the fetus. Elderly patients are noted to have an increased risk of serious adverse reactions, particularly GI bleeding and perforation. The risk of certain adverse events is noted to increase with the duration of use and higher doses.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Noax uno (Tramadol Hydrochloride) is associated with specific, severe toxic manifestations documented in official regulatory labeling. Immediate medical attention must be sought for any suspected overexposure.

A serious overdose may present with life-threatening signs including profound sedation, coma, and respiratory depression (dangerously slow or shallow breathing). The drug's non-opioid activity can cause generalized seizures and carries a risk for Serotonin Syndrome.

Life-Threatening Risks: The primary severe outcomes documented are fatal overdose and life-threatening respiratory depression. Due to the Extended-Release formulation, complications may be delayed, requiring hospital monitoring and supportive care to manage symptoms.

Emergency Actions: Government instructions emphasize contacting emergency services right away if severe signs are observed. While the opioid antagonist Naloxone may be administered to address breathing difficulties, its use must be carefully managed as it is documented to potentially increase the risk of seizures. Treatment focuses on maintaining adequate ventilation and addressing seizure activity. Accidental ingestion of even one tablet by a child can result in a fatal overdose, necessitating immediate emergency response.

Therapeutic Uses of Noax uno

What Noax uno Treats: Main Uses and Benefits

Relief for Persistent and Chronic Pain

Noax uno (Tramadol Hydrochloride Extended-Release) is primarily used for the long-term management of moderate to severe pain, addressing symptoms related to physical discomfort stemming from chronic conditions. The medication is applied in addressing conditions where persistent pain requires continuous symptomatic support when standard options have proven insufficient. The medication is used to address symptoms in conditions such as osteoarthritis and chronic low back pain. This use is generally applied across therapeutic domains where additional symptomatic support is needed.


Improving Function and Comfort Through Sustained Control

The extended-release formulation is specifically designed to provide consistent symptomatic support, which is relevant for easing symptom clusters that may become intense or disruptive throughout the day and night. By effectively managing pain intensity, Noax uno may assist with preserving functional stability and contributes to easing the overall symptom load. This ultimately supports improved comfort during periods of heightened symptoms and is relevant for easing symptoms that interfere with daily comfort. This medication offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, particularly when short-term symptom stabilization is important.


Targeting Elevated Pain Intensity

This medication is commonly used in addressing conditions where functional stability becomes affected by significant symptomatic burden, specifically moderate to severe pain. It is a therapeutic option for addressing conditions where symptoms may intensify temporarily, and offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Persistent Discomfort

The medicine is used for managing continuous pain that is moderate to severe in intensity, often associated with chronic conditions, providing support for extended symptom management.

Eligibility and Restrictions for Use

Official Eligibility Profile for Noax uno

Noax uno (Tramadol Hydrochloride Extended-Release) is approved for use in adults aged 18 years and older for the management of chronic pain. The official regulatory documents strictly define populations who must not use this medicine or who require restricted use.

Absolute Contraindications

Use is contraindicated in several groups due to severe risks. This includes children younger than 12 years of age and children under 18 following tonsillectomy or adenoidectomy. Patients with known hypersensitivity to tramadol or opioids must not use it. It is also contraindicated for patients with significant respiratory depression or acute, severe bronchial asthma, or those currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them.

Population Restrictions

Use is not recommended for patients with severe hepatic impairment or severe renal impairment (creatinine clearance less than 30 mL/min). The FDA also states that prescribing to suicidal or addiction-prone patients is advised against. In the context of pregnancy, prolonged use can result in Neonatal Opioid Withdrawal Syndrome (NOWS), and breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products: Official Regulatory Information

Pharmacodynamic Interaction Constraints

The official regulatory profile highlights the risk of additive effects when co-administered with certain substances. The use of this medicine with alcohol or other Central Nervous System (CNS) depressants is documented to result in profound sedation and severe respiratory depression. Additionally, combining the product with Serotonergic Drugs (including SSRIs, SNRIs, and Triptans) significantly increases the potentially life-threatening risk of Serotonin Syndrome. Co-administration with drugs that reduce the seizure threshold also increases the risk of seizures.

Formal Restrictions and Metabolic Constraints

Certain combinations are formally contraindicated. This includes concurrent use with Monoamine Oxidase Inhibitors (MAOIs) or use within the last 14 days of stopping an MAOI. Co-administration with any other tramadol product is also prohibited. The metabolism of the medicine is affected by the CYP2D6 and CYP3A4 enzyme systems. Inhibitors of these enzymes are documented to increase exposure of the product while reducing levels of the active metabolite. Conversely, the CYP3A4 inducer Carbamazepine is not recommended due to a documented reduction in analgesic efficacy.

Population-Specific Cautions

The extended-release formulation should not be used in patients with documented severe renal impairment (Creatinine Clearance < 30 mL/min) or severe hepatic impairment, as specified in the regulatory labeling.

Mechanism of Action

How Noax uno Works: A Dual Mechanism of Action

Noax uno (Tramadol) operates through a dual, complementary mechanism acting within the central nervous system. Its primary action is mediated by its active metabolite, O-desmethyltramadol ( M1), which functions as an agonist at the mu-Opioid Receptor ( MOR).

the . This receptor binding modulates neuronal activity, resulting in the adjustment of ascending signal transmission.

The second, concurrent mechanism involves the parent compound and its metabolites acting as inhibitors of the reuptake of the neurotransmitters serotonin ( 5-HT) and norepinephrine ( NE). By blocking the SERT and NET transporters, the drug increases the concentration of these monoamines in the synaptic cleft. This increased monoamine availability enhances the signaling of the body's descending inhibitory pathways, which are involved in limiting signal transmission at the level of the spinal cord.

The overall mechanism is defined by the synergistic convergence of mu-Opioid receptor modulation and monoamine reuptake inhibition, leading to a multimodal adjustment of central nervous system signal processing. The formation of the active M1 metabolite is dependent on CYP2D6 enzyme activity, which influences the magnitude of the mu-Opioid component of the drug's effect.

Dosage and Administration Information

How to Use Noax uno

Noax uno, a formulation of Tramadol Hydrochloride Extended-Release, is prescribed for administration via the oral route. Its usage protocol is strictly defined by its extended-release design, which requires consistent daily timing and specific handling to maintain the drug’s sustained delivery mechanism.


Official Administration Guidelines

Usage Aspect Official Instruction
Route & Form Must be taken orally as an extended-release tablet.
Starting Dose (Adult) The initial dose for opioid-naïve patients is typically 100 mg once daily.
Dosing Frequency The tablet is taken once daily (q.d.) at approximately the same time each day.
Maximum Dose The maximum recommended total daily dose of the extended-release product is 300 mg.
Food Relationship May be taken with or without food; consistency in timing is key.
Tablet Integrity The tablet must not be crushed, chewed, split, or dissolved to ensure proper sustained release.

Usage Patterns and Special Populations

This medication is intended for long-term management and requires the dose to be tapered gradually when discontinuation is necessary, adhering to a defined schedule. If a dose is missed, individuals should not take the missed dose or double up; instead, the regimen should resume at the next regularly scheduled time. The use of the extended-release tablet is not recommended for patients with severe renal impairment (CrCl < 30 mL/min) or severe hepatic impairment due to risks associated with delayed elimination and limited dose flexibility. These instructions ensure the consistent delivery necessary for continuous support.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Noax uno

Evidence for Use in Chronic Low Back Pain and Osteoarthritis Pain

Clinical evaluation of Noax uno, the extended-release formulation of tramadol, primarily relies on Randomized Controlled Trials (RCTs) and systematic reviews. Research for chronic low back pain and osteoarthritis has focused on trials enrolling adult individuals with moderate to severe pain. Studies examined outcomes related to pain intensity and physical function (such as movement limitations), monitoring changes over short-term periods. Findings describe patterns observed in these studies compared to placebo. The available evidence for both indications is categorized as having low certainty by reviewers, and the follow-up durations in the main controlled phases often did not extend beyond 12 to 16 weeks.


Evidence for General Chronic Moderate to Severe Pain

Research has also explored the broader evaluation of the medicine for general chronic moderate to severe pain. This evidence is largely derived from Systematic Reviews that aggregate data from RCTs involving diverse conditions, including neuropathic pain and fibromyalgia. These studies monitored changes related to physical discomfort and daily functioning. The findings across this heterogeneous group were mixed and limited by significant variability among the different conditions pooled in the analyses.


Research Gaps and Limitations

A key limitation across the evidence base is the lack of information for long-term outcomes. Long-term effects are not fully established, and data are still emerging regarding sustained patterns of change over many months or years. Additionally, while research involved adults, dedicated comparative evidence is lacking for specific subgroups like older adults with co-existing conditions, meaning results apply primarily to the general populations studied. The overall low certainty of evidence and the need for more objective outcome measures remain recognized limitations in the research record.

Key Studies & References

  1. Tramadol versus placebo for chronic pain: a systematic review with meta-analysis and trial sequential analysis - BMJ Evidence-Based Medicine
  2. Tramadol for the Management of Pain in Adult Patients: A Review of Clinical Effectiveness — An Update - NCBI (CADTH Rapid Response)

Frequently Asked Questions (FAQ)

Common questions about Noax uno (FAQ)


Q: How quickly should a person generally expect Noax uno to start working?

As Noax uno is an extended-release formulation, it is designed to provide a sustained and consistent level of medication over 24 hours. While the immediate-release form of the drug typically starts providing relief within an hour, the extended-release formulation is designed to release the active ingredient slowly for sustained coverage, which differs from the onset observed with immediate-release forms.


Q: Does Noax uno need to build up in the system to be effective?

The extended-release formulation is intended for continuous, around-the-clock dosing for the management of chronic pain. The levels of the drug and its active metabolite in the bloodstream, known as steady-state concentrations, are typically reached after about two days of consistent dosing. Reaching this steady level is generally associated with the intended effect for continuous pain management.


Q: Can women who are planning to become pregnant use Noax uno?

Official warnings state that prolonged maternal use of this class of opioid analgesics during pregnancy can result in physical dependence in the newborn and Neonatal Opioid Withdrawal Syndrome (NOWS). Additionally, chronic opioid use may be associated with reduced fertility, and it is currently unknown whether these effects are reversible after discontinuation.


Q: Are there any specific foods that are known to interact with Noax uno?

Official administration guidelines state the medication can be taken with or without food, emphasizing the importance of consistent daily timing. However, it is noted in some regulatory contexts that consumption of grapefruit juice should be avoided, as it may affect the liver enzyme responsible for breaking down the drug.


Q: What happens if Noax uno is taken with supplements like vitamins or herbal remedies?

Combining the medication with any substance that increases serotonin levels—including certain herbal products or supplements like St. John’s wort—significantly increases the potentially life-threatening risk of Serotonin Syndrome. Interactions with general vitamins are not typically documented in official labeling.


Q: Does Noax uno contain gluten, lactose, or common allergens?

Official drug labels list all inactive ingredients (excipients) used in the tablet formulation. While general regulatory guidance indicates that most oral drug products are unlikely to contain significant amounts of gluten, the full list of excipients is available in the official patient information.


Q: Is it possible for Noax uno to stop working over time?

Studies and official information indicate that if the medication is used for a long time, the body can adapt to the drug, a neurobiological process known as tolerance. This neuroadaptation may affect the level of pain relief experienced. In rare cases, some individuals may also experience increased pain sensitivity, known as hyperalgesia.


Q: Can a person stop taking Noax uno suddenly?

Official regulatory warnings state that the dose must not be stopped suddenly. The dosage must be tapered gradually when discontinuation is necessary, as stopping abruptly can lead to serious opioid withdrawal symptoms, including anxiety, palpitations, and physical symptoms of withdrawal.


Q: Is Noax uno safe to use while breastfeeding?

No. Official documents state that use is not recommended while breastfeeding. Official advice against use is based on the risk of the active substance passing into breast milk and potentially causing serious adverse reactions in the infant, such as excessive sleepiness or breathing problems.


Q: Does Noax uno change the effectiveness of birth control pills?

Official regulatory information indicates that this medication does not affect the effectiveness of hormonal contraception, including the combined birth control pill. However, if the medication causes severe and prolonged vomiting or diarrhea (lasting over 24 hours), the protection provided by oral contraceptives may be compromised.


Q: Is it normal to have vivid dreams when taking Noax uno?

Regulatory documents list unusual dreams as a possible adverse effect. This is a recognized central nervous system (CNS) effect that has been reported. This effect should be observed in the context of other possible CNS effects like dizziness or sedation.


Q: Does Noax uno impact blood pressure or blood sugar levels?

Yes, official safety information documents that this medication may be associated with low blood pressure (hypotension). In rare cases, low blood sugar (hypoglycemia) has also been reported as a serious adverse reaction.


Q: Is Noax uno often prescribed alongside other medicines?

While the drug may be used as part of a comprehensive pain management strategy, the official label highlights extensive restrictions when co-administered with other drugs. Formal restrictions apply, especially to Central Nervous System (CNS) depressants and all Serotonergic Drugs, due to the risks of dangerous interactions.


Q: Is Noax uno available over the counter in any country?

No. The active ingredient in Noax uno is a prescription-only medicine. In the United States, for instance, it is classified by the DEA as a Schedule IV Controlled Substance, meaning it is strictly regulated and requires a valid prescription.


Q: Does Noax uno affect mental clarity or concentration?

The official documentation lists central nervous system effects such as dizziness and sedation as possible adverse reactions. Due to these potential effects on cognitive function, patients are cautioned about performing tasks that require full mental alertness, such as driving or operating heavy machinery.


Q: Is there a generic version of Noax uno available?

Yes. The active ingredient in this medication, Tramadol Hydrochloride, is available in generic extended-release formulations following official regulatory approvals from health authorities.


Q: Are there different strengths of Noax uno available?

Yes. The extended-release tablet formulation is approved and available in multiple dosage strengths. Regulatory prescribing information typically lists strengths such as 100 mg, 200 mg, and 300 mg tablets.


Q: Why do some patient information leaflets list so many possible side effects for Noax uno?

Official regulatory agencies require that all adverse events reported during clinical trials and post-marketing surveillance be documented, regardless of how rare they are. The extensive nature of the lists is required by law for safety monitoring, ensuring comprehensive documentation of all potential health risks.


Q: Is Noax uno a narcotic or controlled substance?

The medication is classified as an opioid analgesic and is regulated in the United States by the Drug Enforcement Administration (DEA) as a Schedule IV Controlled Substance.

How should Noax uno be stored and disposed of?

The storage and disposal of Noax uno (Tramadol Hydrochloride Extended-Release) must follow regulatory requirements to maintain product stability and prevent accidental exposure.

Storage & Handling

Labeled Storage Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environment Keep the original, tightly closed container away from excess heat, moisture, and direct light.
Handling Tablets must be swallowed whole and not crushed, dissolved, or split, as this alters the extended-release mechanism.

Security and Disposal

Official labeling requires the medication to be kept out of the sight and reach of children and pets in a secure location due to the risk of fatal overdose. Expired or unused tablets must be disposed of immediately.

The preferred method of disposal is taking the product to an authorized drug take-back program. If this is not available, the alternative involves mixing the medication with an unappealing substance, sealing the mixture in a bag, and discarding it in the trash, as instructed by regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noax uno found in:

A-Z Index: